Analytical Suites for SUS: LC-MS/HRMS, GC-MS, and ICP-MS


Analytical Suites for SUS: LC-MS/HRMS, GC-MS, and ICP-MS

Published on 09/12/2025

Analytical Suites for SUS: LC-MS/HRMS, GC-MS, and ICP-MS

Within the pharmaceutical industry, ensuring the integrity of drug products and their respective packaging systems is paramount. Extractables and leachables (E&L) are critical components to assess when qualifying single-use systems (SUS) and filters. This article provides a step-by-step guide to the methods and analytical suites used to evaluate these parameters, notably focusing on the use of LC-MS/HRMS (Liquid Chromatography-Mass Spectrometry/High-Resolution Mass Spectrometry), GC-MS (Gas Chromatography-Mass Spectrometry), and ICP-MS (Inductively Coupled Plasma Mass Spectrometry).

Understanding Extractables and Leachables: A Critical Assessment

Extractables and leachables (E&L) testing is vital for understanding the compatibility of pharmaceutical products with their packaging materials. This section aims to elaborate on the significance of E&L testing, the principles behind it, and the regulatory expectations, particularly concerning documents such as the EU GMP Annex 1 and US FDA process validation guidelines.

The extractables are chemical entities released from packaging materials when subjected to solvent extraction, heat, or pressure. In contrast, leachables are those compounds that migrate into the drug product during normal storage conditions. Understanding these components is crucial for ensuring patient safety and product efficacy.

  • Defining Extraction Conditions: It is essential to define the extraction conditions to ensure a genuine representation of the leachables that might be present during actual use.
  • Regulatory Guidance: Compliance with regulatory expectations, especially from bodies like the FDA and EMA, provides a robust framework for E&L testing. For instance, the EMA guidelines underline the importance of risk assessments to determine necessary analytical evaluation thresholds (AET) and dose-based thresholds (DBT).
  • Contaminant Risk Assessment: The risk assessment models proposed by organizations such as the Product Quality Research Institute (PQRI) focus on identifying potential contaminants from single-use systems and establishing acceptable limits.

While performing an E&L risk assessment, it is paramount to consider various factors, including the properties of the drug product, the material of the single-use system, and the conditions of use. Additionally, you must prepare for container closure integrity (CCI) testing to evaluate the packaging’s ability to maintain its barrier properties over the product’s lifecycle.

Selecting the Appropriate Analytical Techniques

When determining the appropriate analytical techniques for E&L testing, it is crucial to select methods that can accurately identify and quantify the leachables at the specified risk thresholds. The primary analytical suites for this purpose are LC-MS/HRMS, GC-MS, and ICP-MS.

1. LC-MS/HRMS

Liquid Chromatography-Mass Spectrometry (LC-MS) and High-Resolution Mass Spectrometry (HRMS) are powerful techniques for analyzing polar and semi-polar compounds. These methods are particularly useful for detecting low molecular weight molecules that are not amenable to gas chromatography.

  • Method Development: Begin by developing a robust method that includes optimization of the mobile phase, column selection, and mass spectrometry settings.
  • Sample Preparation: Sample matrices must be prepared adequately to remove any potential interferences and ensure the detection of relevant extractables and leachables.
  • DETERMINATION OF AET/DBT: Utilize the method to quantify E&L concentrations, allowing for analytical evaluation threshold and dose-based threshold calculations, ensuring compliance with regulatory standards.
  • Data Interpretation: Interpret results carefully, differentiating between true leachables and laboratory artifacts. Confirm findings against appropriate databases.

2. GC-MS

Gas Chromatography-Mass Spectrometry (GC-MS) is particularly effective for volatile and semi-volatile compounds. This method involves the separation of compounds using gas chromatography, followed by mass spectrometry detection.

  • Method Development: Similar to LC-MS, initial method development is critical. Select optimal column types and temperature gradients to enhance resolution and sensitivity.
  • Sample Preparation: To analyze samples through GC-MS, appropriate extraction techniques, such as solid-phase microextraction (SPME), may be employed to ensure successful capture of relevant analytes.
  • Quality Control Measures: Implement quality control measures throughout the analysis, including the use of method blanks and spiked samples, to validate results.

3. ICP-MS

Inductively Coupled Plasma Mass Spectrometry (ICP-MS) is an essential technique for analyzing metallic leachables. It’s capable of detecting elements at trace levels, making it a vital method in E&L assessments.

  • Sample Digestion: Prior to analysis, metals present in plastics or filters must be digested using either acid digestion or microwave-assisted digestion techniques to convert the samples into a suitable form for ICP-MS analysis.
  • Calibration and Validation: Characterize the instrument performance using appropriate calibration standards and validate the method by assessing recovery and precision.
  • Results Interpretation: Ensure that leachable metal concentrations are reported in relevant units and evaluated against established thresholds.

Implementation of E&L Testing in Single-Use Systems Validation

Single-use systems have gained widespread acceptance within the pharmaceutical manufacturing landscape due to their convenience and minimized risk of cross-contamination. The effective validation of these systems is critical to achieving and maintaining compliance with both US FDA and EU regulations.

1. Validation Framework

Establish a rigorous validation framework that encompasses the entire lifecycle of single-use systems, from material selection through to final product use. Key steps include:

  • Material Characterization: Conduct a detailed assessment of the polymer materials used in manufacturing single-use components. This includes an initial evaluation of the potential for extractable and leachable compounds based on the material’s chemical structure.
  • Conducting E&L Studies: Design and implement E&L studies focused on the actual use conditions of the single-use systems. Identify appropriate solvents, extraction conditions, and timeframes to simulate real-world application.
  • Compliance Test Execution: Execute tests in accordance with established protocols for LC-MS/HRMS, GC-MS, and ICP-MS, documenting all findings thoroughly. Results should guide risk management activities as mandated by guidelines such as the FDA and EU GMP Annex 1.

2. Container Closure Integrity Testing

Additionally, CCI testing is imperative for ensuring that packaging maintains its integrity throughout the lifecycle of the product. The applicability of USP guidelines for CCI testing should be embraced here. Common approaches include:

  • Vacuum Decay Testing: This method assesses the ability of a package to maintain a vacuum state, thus indicating the absence of leaks.
  • Pressure Decay Testing: By measuring pressure changes over time, this technique can effectively determine whether a container is compromised.
  • Helium Leak Testing: Utilizing helium as a tracer gas, this sensitive technique can detect even minute leaks that may compromise the product’s integrity.

Addressing Regulatory Expectations and Documentation

Engaging with regulatory authorities is essential for pharmaceutical companies to establish compliance and maintain their operational license. Proper documentation and thorough understanding of regulatory requirements are critical to validating E&L assessments and single-use systems.

1. Documentation Practices

Maintain comprehensive records detailing each step in the validation process. This includes:

  • Method Validation Reports: Provide detailed documentation that validates analytical techniques against predefined acceptance criteria.
  • Study Protocols: Document E&L study designs, analytical methodologies, results, and interpretations clearly to support compliance claims.
  • Training Records: Ensure personnel conducting validations are adequately trained and qualified in regulatory requirements and analytical techniques.

2. Engagement with Regulatory Agencies

Establish communication lines with regulatory authorities such as the FDA, EMA, and MHRA to ensure that your testing methodologies align with current industry standards and expectations. Regular updates to testing protocols as per guidance documents are essential to maintain compliance.

Conclusion

As pharmaceutical professionals, understanding the intricate methodologies and regulatory frameworks surrounding extractables and leachables is paramount. Utilizing analytical suites such as LC-MS/HRMS, GC-MS, and ICP-MS effectively enables the rigorous assessment of single-use systems and filters. By adhering to established regulatory guidelines and maintaining rigorous documentation practices, pharmaceutical companies can ensure the safety and efficacy of their drug products, thus fostering trust among healthcare providers and patients alike.